SCHEMBL1852290

SCHEMBL1852290

COC(=O)c1ccc(-c2nc3c(oc4ccccc43)c(=O)[nH]2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 2/20 0.63
PIM1 P11309 6/20 0.54
PIM3 Q86V86 6/20 0.54
CSNK2A2 P19784 6/20 0.54
CSNK2B P67870 6/20 0.54
PIM2 Q9P1W9 5/20 0.54
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
KDM4E B2RXH2 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 2/20 0.51
GLA P06280 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
IDO1 P14902 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2220413 0.79 PIM1 (0.55) TNKSPIM1PIM3CSNK2A2CSNK2B
SCHEMBL2219360 0.77 PIM1 (0.60) TNKSPIM1PIM3CSNK2A2CSNK2B
SCHEMBL1849708 0.77 CSNK2B (0.60) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL17829676 0.76 TNKS (0.67) TNKSALDH1A1HPGDKDM4ENPC1
SCHEMBL12439433 0.76 ALDH1A1 (0.57) TNKSPIM1PIM3CSNK2A2CSNK2B
SCHEMBL5371438 0.74 TNKS (0.67) TNKSALDH1A1HPGDKDM4ENPC1
SCHEMBL9608554 0.73 MAPT (0.71) TNKSALDH1A1HPGDKDM4ENPC1
SCHEMBL13650745 0.73 CSNK2B (0.73) TNKSPIM1PIM3CSNK2A2CSNK2B
SCHEMBL16965178 0.71 TNKS (0.64) TNKSALDH1A1HPGDKDM4ENPC1
SCHEMBL15304529 0.71 ALDH1A1 (0.68) PIM1PIM3CSNK2A2CSNK2BPIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US claimed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP claimed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO claimed
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 TNKS 3122/4885PIM1 1977/4885PIM3 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.